Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, tolerability, and pharmacokinetics of NNC0194-0499 in Japanese and non-Asian males
jRCT2071200100Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2021
- Modality
- Hormonal Peptides → Native Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing NNC0194-0499 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events (TEAEs). Started Feb 2021; status: completed.
02
Drugs
nn9500
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2071200100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200100.